790 Memorial Drive, Suite 3A
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients. Work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing islet cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes. Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of- the-art device to provide a true replacement for the missing islet cells in a diabetic patient without immunosuppression. Semma Therapeutics is working to bring new therapeutic options to the clinic and ? improve the lives of patients with diabetes. The company is headquartered in Cambridge, MA.
Founder: Doug Melton and Felicia Pagliuca
CEO: Robert Millman, JD
CMO: Moses Goddard, MD
CFO: David Cordo
Please click here for Semma Therapeuticsl job opportunities.